Wednesday was not a dip. It was a verdict. UnitedHealth closed at $349.91, down $39.77 or 10.21%. Humana fell 12.98% to $385.78. CVS Health closed 5.2% lower at about $81.35. The Dow lost 561 points, with UNH alone accounting for most of that damage. And this morning, the Federal Register publishes the CRUSH rule, with comments due January 19, 2027.
The question that matters for anyone holding these stocks is not what the rule says. It is whether institutions are treating this as a permanent earnings reset or a rulemaking fight they have seen before and won.
What the Rule Actually Does
The provision that matters most for insurers would revive a version of the agency’s Medicare Advantage Risk Adjustment Data Validation (RADV) approach: it would let CMS extrapolate audit findings from a sample of enrollees across an entire Medicare Advantage contract, beginning with payment year 2018 audits. CMS estimates the revised audit methodology could recover approximately $9 billion per payment year in Medicare Advantage overpayments. That is an industry-wide figure, not a UNH-specific one, and nobody has sized individual exposure yet.
There is also a provision that changes the math structurally: CMS is proposing to codify that it would not apply a fee-for-service adjuster when calculating RADV overpayments. That adjuster was the buffer that softened prior clawback estimates. Its absence is why Wednesday’s selloff ran deeper than Tuesday’s.
The Bull Case: This Gets Litigated, Not Implemented
Oppenheimer is one of the louder voices arguing the market overshot, pointing to the legal vulnerability of CMS’s RADV framework in recent court history and arguing that the headline budget figure in the CRUSH proposal largely reflects recouping repayments rather than broad savings to healthcare programs.
The legal history supports some skepticism. The rule has precedent working against it: parts of CMS’s 2023 RADV final rule were vacated by a federal judge in Texas on September 25, 2025, after Humana’s lawsuit. The court faulted CMS’s notice-and-comment process for key pieces of the approach, including its treatment of actuarial equivalence and the fee-for-service adjuster. CRUSH is essentially a re-proposal of that same direction, this time with a 60-day comment window and a more careful administrative record. Whether that is enough to survive another challenge is the bet institutions are being asked to make right now.
Investment bank forecasts remain broadly positive for UnitedHealth, Humana and CVS Health, although recent price targets largely predate the latest regulatory-driven decline. Wall Street consensus on UNH remains Buy, with an average target near $476, implying roughly 36% upside from Wednesday’s close.
The Bear Case: History Does Not Repeat This Time
The bulls need the courts to cooperate again. That is not a small ask. CMS has spent the intervening year building a cleaner procedural record, and the agency has said it intends to conduct program-integrity rulemaking of this kind on an annual basis going forward. Even if CRUSH is vacated, the next version arrives in 2027.
Mizuho analyst Ann Hynes identified UnitedHealth and Humana as the insurers most affected by the proposed changes, followed by CVS Health, Elevance Health, Centene and Molina Healthcare. That ordering matters. UnitedHealth faces significant exposure because it operates the country’s largest Medicare Advantage business. Humana is worse positioned still: Medicare Advantage is not a segment for HUM, it is essentially the entire company. A sustained audit regime without a fee-for-service adjuster would pressure margins for years, not quarters.
Rising medical costs and elevated utilization are further pressuring insurers’ margins, making UnitedHealth’s earnings outlook uncertain even before the CRUSH rule is finalized. The regulatory headwind lands on a sector already fighting medical cost inflation.
Stocks to Watch
UNH is the purest test of the litigation thesis. If CRUSH survives its first court challenge, the stock has not found a floor yet. If it is vacated again, Wednesday’s close near $350 may look like one of the better entries of 2026.
HUM has less margin for error. Its Medicare Advantage concentration means any persistent audit liability lands with less diversification to absorb it. The 13% single-day drop reflects that asymmetry.
ELV and CNC sold off hard, but their more diversified books give them more room to recover faster if the legal challenge succeeds. Watch them as a read on how quickly institutional money rotates back into managed care.
CVS is mid-restructuring, splitting its retail and insurance arms, which complicates the CRUSH exposure picture. The 5.2% decline may actually understate how messy this gets if the audit methodology is applied to its Aetna book during a corporate separation.
The comment period closes January 19. That is eight weeks for industry lawyers, management teams and lobbyists to build the record for the next courtroom fight. Until then, every bounce in this group is a bet on procedure, not fundamentals.
